Annual Report

Overview

The report describes 2016 as a transition year, including board and senior-management changes. Consolidated total revenue was reported as 40,740 thousand U.S. dollars, with licensing revenue of 25,555 thousand and product revenue of 15,185 thousand. The company launched Actikerall and Beteflam in Canada and maintained four commercial products. It also recognized a $29.2 million impairment charge related to U.S. intangible assets and goodwill.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2016
Period: Ends 31 December 2016
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services